This list of stocks was generated by tracking the most popular ticker searches on the Benzinga Pro real-time news
platform.
Readers can rely on this daily list to offer insight into which stocks retail investors are most interested in during a
given trading session. In addition to providing the list itself, this article offers a quick glimpse into why a certain stock may
be trending.
- Shares of Facebook, Inc. (NASDAQ: FB)
were up 4.09 percent to $152.20 after the
company reported Q3 earnings.
-
General Electric Company (NYSE: GE)
shares were down 1.28 percent to $10.05. Moody’s Investors Service downgraded the company’s rating.
- Shares of Achieve Life Sciences, Inc. (NASDAQ: ACHV) fell 1.46 percent to $2.02. The company on Tuesday announced the
initiation of a Phase 2b trial of ORCA-1; A program aimed to evaluate the effectiveness of cytisinicline for smoking cessation..
-
Electro Scientific Industries, Inc. (NASDAQ: ESIO) shares rose 1.79 percent to $29.02. The company on Tuesday reported
strong earnings as well as an impending acquisition by MKS Instruments.
- Shares of Apple Inc. (NASDAQ: AAPL)
rose 2.85 percent to $219.41 after the tech giant released
a new line of products, like the MacBook Air and the new iPad Pro.
-
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) shares surged 4.17 percent to $129.18 in light of
success surrounding “Red Dead Redemption 2.”
- Shares of Daxor Corp. (NYSE: DXR) fell
24.43 percent to $6.65. On Tuesday, the company announced new data in the Journal of the American College of Cardiology.
-
Strongbridge Biopharma plc. (NASDAQ: SBBP) shares rose 58.02 percent to $6.40 as the company entered into an
agreement to acquire the U.S. and Canadian rights to Macrilen.
- Shares of Under Armour, Inc. (NYSE: UA)
fell 5.48 percent to $19.82 after
rising nearly 30 percent Tuesday following earnings.
-
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares rose 12.5 percent to $0.72 after announcing the Phase 3
study of its treatment for PTSD.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.